- Home
- SLDP vs AVIR Comparison
SLDP vs AVIR Comparison
Compare SLDP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- AVIR
- Stock Information
- Founded
- SLDP 2011
- AVIR 2012
- Country
- SLDP United States
- AVIR United States
- Employees
- SLDP N/A
- AVIR N/A
- Industry
- SLDP Electrical Products
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- SLDP Energy
- AVIR Health Care
- Exchange
- SLDP Nasdaq
- AVIR Nasdaq
- Market Cap
- SLDP 230.9M
- AVIR 247.5M
- IPO Year
- SLDP N/A
- AVIR 2020
- Fundamental
- Price
- SLDP $1.66
- AVIR $3.37
- Analyst Decision
- SLDP Buy
- AVIR Hold
- Analyst Count
- SLDP 4
- AVIR 1
- Target Price
- SLDP $2.75
- AVIR $6.88
- AVG Volume (30 Days)
- SLDP 9.9M
- AVIR 528.5K
- Earning Date
- SLDP 02-25-2025
- AVIR 02-26-2025
- Dividend Yield
- SLDP N/A
- AVIR N/A
- EPS Growth
- SLDP N/A
- AVIR N/A
- EPS
- SLDP N/A
- AVIR N/A
- Revenue
- SLDP $18,026,000.00
- AVIR N/A
- Revenue This Year
- SLDP $2.53
- AVIR N/A
- Revenue Next Year
- SLDP $95.43
- AVIR N/A
- P/E Ratio
- SLDP N/A
- AVIR N/A
- Revenue Growth
- SLDP N/A
- AVIR N/A
- 52 Week Low
- SLDP $1.00
- AVIR $2.75
- 52 Week High
- SLDP $2.70
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- SLDP 51.92
- AVIR 55.56
- Support Level
- SLDP $1.49
- AVIR $3.11
- Resistance Level
- SLDP $1.81
- AVIR $3.60
- Average True Range (ATR)
- SLDP 0.27
- AVIR 0.13
- MACD
- SLDP -0.05
- AVIR 0.00
- Stochastic Oscillator
- SLDP 14.05
- AVIR 53.17
About SLDP Solid Power Inc.
Solid Power Inc is engaged in developing all-solid-state battery cell technology to enable the next generation of batteries for the EV and other markets. The company's planned business model is to license its all-solid-state battery cell designs and manufacturing know-how to top tier battery manufacturers or automotive original equipment manufacturers and to sell its sulfide-based solid electrolyte for incorporation into all-solid-state battery cells.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).